“Chemotherapy will become just a bad memory”

I reported previously (3rd Sep) of Gilead’s $11.9 billion buyout of Kite – a biotech founded by Israel’s Professor Arie Belldegrun. Kite’s CAR-T technology cures non-Hodgkin lymphoma that kills 7,000 patients annually in the US alone. Prof Belldegrun gave his first interview since the deal.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *